Literature DB >> 28012511

The use of the FLACC pain scale in pediatric patients undergoing adenotonsillectomy.

Andrew J Redmann1, Yu Wang2, James Furstein3, Charles M Myer4, Alessandro de Alarcón4.   

Abstract

OBJECTIVES: 1) Determine the usage rate of opioid pain medication after adenotonsillectomy (T&A). 2) Review the use of the Face, Legs, Activity, Cry, Consolability (FLACC) pain scale for T&A patients 3) Determine the rate of postoperative physician contacts for pain related complaints.
METHODS: A retrospective case series review was performed on 125 pediatric patients undergoing T&A and subsequent 23-hour postoperative observation at an academic tertiary care center from June-August of 2015. Postoperative pain scores using the FLACC pain scale, the utilization of opioid pain medications, and the number of postoperative contacts for pain were recorded.
RESULTS: Average age of patients was 5.7 years and 50% were female. 90% of T&A's were performed for adenotonsillar hypertrophy. The post-tonsillectomy hemorrhage rate was 4%. 70 (56%) patients required postoperative opioid pain medication, with (30) 43% of these patients requiring more than one dose. The mean number of opioid doses was 1.64 ± 0.9 and was not related to age, weight or gender. FLACC scores were highly associated (spearman correlation 0.77) with the amount of opioid medication given. Mean FLACC scores decreased over time after T&A. 20% of patients contacted a physician for unsatisfactory pain control postoperatively with 6% requiring emergency department visits and 14% contacting the office via phone call.
CONCLUSIONS: A significant portion of pediatric patients undergoing T&A require postoperative opioids for pain control. The FLACC scale is a valuable way of quantifying post-operative T&A pain in pediatric patients. Despite routine pain management postoperatively, a significant proportion of patients require contact with a physician postoperatively for pain management.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Adenotonsillectomy; Postoperative pain control; Sleep disordered breathing

Mesh:

Substances:

Year:  2016        PMID: 28012511     DOI: 10.1016/j.ijporl.2016.11.016

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  6 in total

1.  The validity of simplified self-report pain intensity assessment tools in preschool-age children undergoing adenotonsillectomy.

Authors:  Ali Bayram; Mustafa Şahin; Serkan Altıparmak; Aykut Kuru
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-05-09       Impact factor: 2.503

2.  Triage through telemedicine in paediatric emergency care-Results of a concordance study.

Authors:  Angelika Beyer; Kilson Moon; Peter Penndorf; Thomas Hirsch; Uta Zahn-Tesch; Wolfgang Hoffmann; Holger N Lode; Neeltje van den Berg
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

Review 3.  Postoperative Nausea and Vomiting in Pediatric Patients.

Authors:  Anthony L Kovac
Journal:  Paediatr Drugs       Date:  2020-10-27       Impact factor: 3.022

4.  Effect of Cold Diet and Diet at Room Temperature on Post-Tonsillectomy Pain in Children.

Authors:  Mojtaba Meybodian; Mohammadhossein Dadgarnia; Mohammadhossein Baradaranfar; Sedighe Vaziribozorg; Mahzad Mansourimanesh; Mohammad Mandegari; Nasir Saeidi Eslami
Journal:  Iran J Otorhinolaryngol       Date:  2019-03

5.  The Effects of Different Doses of Alfentanil and Dexmedetomidine on Prevention of Emergence Agitation in Pediatric Tonsillectomy and Adenoidectomy Surgery.

Authors:  Yan-Zhuo Zhang; Xiong-Li Wei; Bin Tang; Yuan-Yuan Qin; Min Ou; Xiao-Hong Jiang; Yu-Feng Tan; Mao-Ying Ye
Journal:  Front Pharmacol       Date:  2022-02-02       Impact factor: 5.810

Review 6.  Detection and assessment of postoperative pain in children with cognitive impairment: A systematic literature review and meta-analysis.

Authors:  Anna Pizzinato; Ilaria Liguoro; Anna Pusiol; Paola Cogo; Alvisa Palese; Enrico Vidal
Journal:  Eur J Pain       Date:  2022-03-17       Impact factor: 3.651

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.